CSIMarket
 


Akers Biosciences Inc   (AKER)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

AKER's Income from Cont. Operations Growth by Quarter and Year

Akers Biosciences Inc 's Income from Cont. Operations results by quarter and year




AKER Income from Cont. Operations (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - -1.34 -3.84 -4.17
III Quarter September -2.92 -0.84 -3.08 -1.18
II Quarter June -3.63 -0.79 -2.07 -0.82
I Quarter March -3.54 -0.92 -1.86 -1.35
FY   -10.09 -3.89 -10.85 -7.52



AKER Income from Cont. Operations third quarter 2020 Y/Y Growth Comment
Akers Biosciences Inc in the third quarter recorded loss from continued operations of $ -2.92 millions.

According to the results reported in the third quarter, Akers Biosciences Inc achieved the best Income from Cont. Operations growth in Biotechnology & Drugs industry. While Akers Biosciences Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter.




AKER Income from Cont. Operations ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Akers Biosciences Inc 's third quarter 2020 Income from Cont. Operations $ -2.92 millions AKER's Income Statement
Akers Biosciences Inc 's third quarter 2019 Income from Cont. Operations $ -0.84 millions Quarterly AKER's Income Statement
New: More AKER's historic Income from Cont. Operations Growth >>


AKER Income from Cont. Operations (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Akers Biosciences Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AKER's III. Quarter Q/Q Income from Cont. Operations Comment
Although Akers Biosciences Inc in the III. Quarter 2020 admitted loss from continued operations of $ -2.92 millions, some analyst mentioned, that this show recovery compare to the -3.63 millions in the second quarter.

Within Biotechnology & Drugs industry Akers Biosciences Inc achieved highest sequential Income from Cont. Operations growth. While Akers Biosciences Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AKER's III. Quarter Q/Q Income from Cont. Operations Comment
Despite the fact, that Akers Biosciences Inc in the III. Quarter 2020 admitted loss from continued operations of $ -2.92 millions, it should be said, that current results show improvement compare to the -3.63 millions in the second quarter.

Within Biotechnology & Drugs industry Akers Biosciences Inc achieved highest sequential Income from Cont. Operations growth. While Akers Biosciences Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Akers Biosciences Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
Cumulative Income from Cont. Operations 12 Months Ending $ -11.42 $ -9.34 $ -6.51 $ -3.89 $ -6.39
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Akers Biosciences Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -11 millions in the Sep 30 2020 period.
The business is detiriorating as the cumulative loss from continued operations is getting bigger from $ -9.34 millions in the twelve months ending a quarter before and $ -3.63 millions from the TTM period ending Sep 30 2019.

Akers Biosciences Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Akers Biosciences Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -11 millions in the Sep 30 2020 period.
The situation is getting worse as the cumulative loss from continued operations is inflating from $ -9.34 millions in the twelve months ending a quarter before and $ -3.63 millions for the twelve months ending in the quarter Sep 30 2019 María Ángeles González wrote.

Akers Biosciences Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Drugs Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
AKER's Income from Cont. Operations Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for AKER's Competitors
Income from Cont. Operations Growth for Akers Biosciences Inc 's Suppliers
Income from Cont. Operations Growth for AKER's Customers

You may also want to know
AKER's Annual Growth Rates AKER's Profitability Ratios AKER's Asset Turnover Ratio AKER's Dividend Growth
AKER's Roe AKER's Valuation Ratios AKER's Financial Strength Ratios AKER's Dividend Payout Ratio
AKER's Roa AKER's Inventory Turnover Ratio AKER's Growth Rates AKER's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2020 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2020
Nature s Sunshine Products inc   430.64 %$ 430.644 millions
Inspyr Therapeutics Inc   400.24 %$ 400.238 millions
Phibro Animal Health Corp  389.15 %$ 389.145 millions
Amphastar Pharmaceuticals Inc   387.09 %$ 387.093 millions
Novocure Limited  381.04 %$ 381.036 millions
Antares Pharma Inc   379.00 %$ 379.003 millions
Abiomed Inc   375.96 %$ 375.962 millions
Integrated Biopharma Inc  233.65 %$ 233.654 millions
Laboratory Corporation Of America Holdings  218.42 %$ 218.416 millions
Catalyst Pharmaceuticals Inc   217.97 %$ 217.970 millions
Quest Diagnostics Inc  161.50 %$ 161.504 millions
Procyon Corp  161.33 %$ 161.326 millions
Infusystem Holdings Inc  159.03 %$ 159.031 millions
Luna Innovations Inc  152.14 %$ 152.143 millions
The Pennant Group Inc   144.43 %$ 144.426 millions
Universal Health Services Inc  141.99 %$ 141.987 millions
Select Medical Holdings Corp  137.24 %$ 137.241 millions
Apollo Medical Holdings Inc   136.75 %$ 136.748 millions
Bio techne Corp  131.94 %$ 131.942 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

NGTF's Profile

Stock Price

NGTF's Financials

Business Description

Fundamentals

Charts & Quotes

NGTF's News

Suppliers

NGTF's Competitors

Customers & Markets

Economic Indicators

NGTF's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071